Agios Pharma (AGIO) Posts Smaller-than-Expected Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120
May 7, 2015 7:30 AM EDTAG-221: Ongoing Phase 1 study expanded by an additional 125 patients in selected AML (acute myeloid leukemia) populations AG-120: Ongoing Phase 1 hematologic malignancy study expanded by 175 patients in three cohorts, including 125 patients in a defined AML population EHA: Abstracts for three lead clinical programs accepted for presentation at the 20th Congress of the European Hematology Association (EHA)
CAMBRIDGE, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported financial results and business... More
